Summary & Overview
CPT 86409: Neutralizing Antibody Titer Assay
CPT code 86409 represents the technical laboratory procedure to measure neutralizing antibody titers against SARS–CoV–2 in specimens such as plasma. This assay identifies the concentration of antibodies that inhibit viral activity and is used to document prior infection and potential immune response following infection or exposure. Nationally, neutralizing antibody testing has clinical and public health relevance for serosurveillance, convalescent plasma assessment, and research contexts, though clinical use varies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, typical service setting, and which payers commonly cover or recognize the test. The publication also summarizes available benchmark considerations, relevant coding context, and operational notes for laboratory billing practices.
This summary provides clinicians, laboratory managers, and revenue cycle professionals with a clear statement of what CPT code 86409 covers, why the assay matters clinically, and what to expect when preparing claims and documentation for national payers. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 86409 describes a laboratory technical procedure to measure the titer (concentration) of neutralizing antibodies in a specimen, such as plasma. The test assesses the level of antibodies that neutralize SARS–CoV–2, the virus that causes COVID-19, and can indicate prior infection and potential immune protection.
Service type: Laboratory — quantitative neutralizing antibody assay (technical component)
Typical site of service: Clinical laboratory or hospital laboratory (specimen processing and analysis)
Clinical & Coding Specifications
Clinical Context
A 45-year-old outpatient presents to a hospital-affiliated laboratory after recent recovery from COVID-19 and requests quantitative assessment of neutralizing antibodies. The clinician documents prior symptomatic SARS–CoV–2 infection (or completed COVID-19 vaccination series) and orders a neutralizing antibody titer to evaluate immune response for research enrollment, return-to-work counseling, or high-risk occupational exposure assessment. A phlebotomist obtains a blood specimen (serum or plasma) in an ambulatory clinic or outpatient lab; the specimen is sent to the laboratory. A medical laboratory technologist or lab analyst performs the technical assay to quantify neutralizing antibody concentration using validated methods (e.g., virus neutralization assay or surrogate assays) and reports a titer result in the patient’s laboratory information system. Results are routed to the ordering provider and placed in the electronic health record for clinical interpretation and follow-up. Typical sites of service include hospital outpatient laboratories, independent clinical laboratories, and large ambulatory clinic labs. The service is strictly a technical laboratory analysis of specimen neutralizing antibody titer and does not include clinician interpretation time or patient-facing services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation component if applicable (rare for purely technical assays). |